Patents by Inventor Laurent Gauthier

Laurent Gauthier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240270865
    Abstract: The disclosure relates to methods and compositions for the treatment of cancer. Specifically, the disclosure relates to methods for administering anti-CD73 antibodies, and to methods for using anti-CD73 antibodies for the treatment of cancers, preferably HER2-positive gastric adenocarcinoma or a gastroesophageal junction adenocarcinoma in an individual.
    Type: Application
    Filed: August 6, 2021
    Publication date: August 15, 2024
    Inventors: LAURENT GAUTHIER, CARINE PATUREL, IVAN PERROT
  • Publication number: 20240253803
    Abstract: An alveolar structure of an acoustic damping panel which is configured for damping at least one sound wave of a sound frequency, wherein the alveolar structure comprises at least one attached element, separate from partitions, and configured for vibrating at a frequency substantially equal to the sound frequency of the sound wave to be damped. Also a method for producing such an alveolar structure, an acoustic damping panel comprising at least one such alveolar structure, and an aircraft comprising at least one such acoustic damping panel.
    Type: Application
    Filed: January 29, 2024
    Publication date: August 1, 2024
    Inventors: François PONS, Laurent CAZEAUX, Arnulfo CARAZO MENDEZ, Florent MERCAT, Alexandre BELLANGER, Laurent PRESSEQ, Maxime GAUTHIER, Manuel TEIGNE, Philippe WESSEL, Joelle BONNEFONT
  • Publication number: 20240253802
    Abstract: An alveolar structure of an acoustic damping panel which is configured for damping at least one sound wave at a sound frequency, wherein the alveolar structure comprises at least one partition provided with at least one cavity configured such that the partition vibrates at a vibrational frequency substantially equal to the sound frequency of the sound wave to be damped. Also a method for producing such an alveolar structure, an acoustic damping panel comprising at least one such alveolar structure, and an aircraft comprising at least one such acoustic damping panel.
    Type: Application
    Filed: January 29, 2024
    Publication date: August 1, 2024
    Inventors: François PONS, Laurent CAZEAUX, Arnulfo CARAZO MENDEZ, Florent MERCAT, Alexandre BELLANGER, Laurent PRESSEQ, Maxime GAUTHIER, Manuel TEIGNE, Philippe WESSEL, Joelle BONNEFONT
  • Publication number: 20240199750
    Abstract: Multi-specific proteins that bind to NKp46 and a cytokine receptor on NK cells, and optionally that further bind CD16A on NK cells, and that also bind to an antigen of interest (e.g. a cancer antigen) on a target cell (e.g. a cancer cell). The multi-specific proteins are capable of increasing NK cell cytotoxicity toward a target cell that expresses the antigen of interest (e.g., a cell that contributes to disease, a cancer cell).
    Type: Application
    Filed: March 24, 2022
    Publication date: June 20, 2024
    Inventors: Stephanie CORNEN, Laurent GAUTHIER, Yannis MOREL, Olivier DEMARIA
  • Publication number: 20240174748
    Abstract: The application pertains to NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Application
    Filed: February 5, 2024
    Publication date: May 30, 2024
    Inventors: LAURENT GAUTHIER, NADIA ANCERIZ, ARIANE MOREL, BENJAMIN ROSSI
  • Publication number: 20240141042
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infections disease.
    Type: Application
    Filed: October 20, 2023
    Publication date: May 2, 2024
    Inventors: Laurent GAUTHIER, Nadia ANCERIZ, Ariane MOREL, Benjamin ROSSI
  • Publication number: 20240124579
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Application
    Filed: December 27, 2023
    Publication date: April 18, 2024
    Inventors: LAURENT GAUTHIER, SIMON KOLLNBERGER, BENJAMIN ROSSI, HÉLÈNE SICARD, CARINE PATUREL, STÉPHANIE CORNEN, STÉPHANIE ZERBIB
  • Patent number: 11958907
    Abstract: This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5? nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: April 16, 2024
    Assignee: INNATE PHARMA
    Inventors: Ivan Perrot, Carine Paturel, Laurent Gauthier
  • Patent number: 11891444
    Abstract: NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: February 6, 2024
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
  • Publication number: 20240034816
    Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-? receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).
    Type: Application
    Filed: September 19, 2023
    Publication date: February 1, 2024
    Inventors: Nicolas GOURDIN, Laurent GAUTHIER, Alexandre TANG, Marielle CHIRON, Angela VIRONE-ODDOS, Alessandro MASIERO, Jochen BENINGA, Ingo FOCKEN, Sambasiva RAO, Yanfeng ZHOU, Leila SEVIGNY
  • Patent number: 11858990
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: January 2, 2024
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Simon Kollnberger, Benjamin Rossi, Hélène Sicard, Carine Paturel, Stéphanie Cornen, Stéphanie Zerbib
  • Publication number: 20230416383
    Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-? receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS).
    Type: Application
    Filed: April 28, 2023
    Publication date: December 28, 2023
    Inventors: Marielle CHIRON, Angela Virone-Oddos, Laurent Gauthier
  • Patent number: 11845795
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: December 19, 2023
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
  • Patent number: 11692039
    Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-? receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS).
    Type: Grant
    Filed: December 30, 2021
    Date of Patent: July 4, 2023
    Inventors: Marielle Chiron, Angela Virone-Oddos, Laurent Gauthier
  • Patent number: 11623954
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: April 11, 2023
    Assignee: INNATE PHARMA
    Inventors: Stéphanie Cornen, Benjamin Rossi, Nicolai Wagtmann, Laurent Gauthier
  • Publication number: 20230025732
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: June 30, 2022
    Publication date: January 26, 2023
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • Publication number: 20220340661
    Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.
    Type: Application
    Filed: June 29, 2022
    Publication date: October 27, 2022
    Inventors: NADIA ANCERIZ, MATHIEU BLERY, LAURENT GAUTHIER, CARINE PATUREL
  • Publication number: 20220213202
    Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-? receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS).
    Type: Application
    Filed: December 30, 2021
    Publication date: July 7, 2022
    Inventors: Céline AMARA, Céline NICOLAZZI, Marielle CHIRON, Francis DUFFIEUX, Jochen BENINGA, Angela VIRONE-ODDOS, Laurent GAUTHIER, Ariane THIELENS, Benjamin ROSSI
  • Patent number: 11377503
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: July 5, 2022
    Assignee: INNATE PHARMA
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • Patent number: 11377492
    Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: July 5, 2022
    Assignee: INNATE PHARMA
    Inventors: Nadia Anceriz, Mathieu Blery, Laurent Gauthier, Carine Paturel